- Home
- Equipment
- north america
- in vivo preclinical
Show results for
Refine by
In Vivo Preclinical Equipment Supplied In North America
9 equipment items found
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Our approach has demonstrated monotherapy activity, reducing tumor volume in a mouse xenograft model of renal cell carcinoma. Recent high profile publications provide preclinical in vivo rationale for monotherapy and combinations with immuno-oncology agents, kinase inhibitors, and chemotherapy. Optimization of oral lead compounds is ...
Manufactured by:Iasis Molecular Science based inSpokane, WASHINGTON (USA)
Our platform No. 1 antiseptics are a family of novel silver-based complexes for the treatment of wound infections and for use as the active component of antimicrobial medical device coatings. These antiseptics offer excellent potency against drug-resistant pathogens, little concern of selection for resistance, lower cellular toxicity, and process benefits not found with commercial antiseptics. ...
Manufactured by:Vascudyne, Inc. based inStillwater, MINNESOTA (USA)
Our proprietary TRUE Tissue technology platform is currently available for investigational use only. TRUE Tissue developed from cells isolated from donor tissue and is 100% biological. There are no synthetic materials or chemical fixation used, and implanted tissues are completely cell-derived and acellular. That’s how we make tissues that are TRUE to ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and angiogenic processes and the substitution of β-amyloid for ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic leukemia (ALL) and relapsed / refractory diffuse large B-cell lymphoma (DLBCL). While ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
EZM 2302 is an inhibitor of coactivator-associated arginine methyltransferase 1 (CARM1) with an IC50 of ...
Manufactured by:Inovotion Sas based inLa Tronche, FRANCE
INOVOTION has developed a unique, highly sensitive and reproducible assay. It is applicable to all preclinical oncology and immuno-oncology drug discovery programs, and monitors the growth and metastatic dissemination of human tumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic ...
Manufactured by:Vascudyne, Inc. based inStillwater, MINNESOTA (USA)
Synthetic vascular grafts currently used in clinic have poor long term outcomes and low patency rates. Hyperplasia, calcification, foreign body immune response, infection, and atheroma formation are commonly encountered limiting the use of synthetic grafts, with none available for small diameter applications like coronary ...